Fig. 4: Verteporfin-NP also inhibits angiogenesis-associated genes in vitro in human TNBC cells.
From: A triple-drug nanotherapy to target breast cancer cells, cancer stem cells, and tumor vasculature
A Schematic showing that HIF-1α is a master regulator in angiogenesis and other tumorigenic processes. B Luciferase reporter activity of HIF-1α activities in MDA-MB-231 cells treated with control DMSO, paclitaxel (25 nM), verteporfin (1.25 µM), CA4 (25 nM), and different combinations for 24 hrs. C RT-qPCR analysis showing the changes of VEGF gene expression in MDA-MB-231 cells after 24 hrs of treatment with E (empty-NP), 25 nM P (paclitaxel-NP), 1.25 µM V (verteporfin-NP), 25 nM C (combretastatin-NP), and different combinations. Data are expressed as mean ± SD, n = 3. *P < 0.05, **P < 0.01.
